What are the diagnostic criteria for acquired hemophilia?

Diagnostic Criteria for Acquired Hemophilia A

The diagnosis of acquired hemophilia A should be considered whenever a patient presents with acute or recent onset bleeding accompanied by an unexplained isolated prolonged aPTT, confirmed by demonstrating reduced factor VIII activity and the presence of factor VIII inhibitors. 1

Core Diagnostic Triad

The diagnosis rests on three essential laboratory findings:

1. Isolated prolonged activated partial thromboplastin time (aPTT) - unexplained and not correcting with normal plasma
2. Markedly reduced factor VIII activity (FVIII:C) - typically very low levels
3. Presence of factor VIII inhibitors - demonstrated by Bethesda or modified Bethesda assay 1

Clinical Presentation Patterns

Classic Presentation

• No prior bleeding history - patients typically have no personal or family history of bleeding disorders 1, 2
• Spontaneous bleeding - often severe, into skin, muscles, or soft tissues
• Elderly or postpartum patients - highest risk groups 1

Critical Caveat

Not all patients present with active bleeding at diagnosis - approximately 10% have no bleeding symptoms but remain at high risk, particularly before procedures or surgery 3. Therefore, an isolated prolonged aPTT should always be investigated further irrespective of clinical findings 1.

Laboratory Diagnostic Algorithm

Step 1: Initial Screening

When aPTT is prolonged:

• Perform mixing studies with both immediate and 2-hour incubation 1
• FVIII inhibitors are time and temperature-dependent, so immediate mixing alone is insufficient 4
• Prolongation after 1-2 hour incubation compared to immediate mix is typical of FVIII autoantibodies 1

Important Pitfall: Immediate correction of aPTT does not exclude AHA - if clinical presentation is suggestive, proceed with specific factor assays regardless of mixing study results 1, 4

Step 2: Specific Factor Assays

• Measure FVIII, IX, XI, and XII levels in all patients with prolonged aPTT and suggestive clinical picture 1
• Perform these assays in parallel with mixing studies to facilitate early diagnosis 1

Step 3: Inhibitor Quantification

• Use Bethesda or modified Bethesda (Nijmegen) assay to quantify the inhibitor 5, 3
• If FVIII in patient sample is >5 IU/dL at diagnosis, perform heat inactivation before inhibitor assays 4

Key Limitation: The Bethesda assay only provides a rough estimate of inhibitor potency in AHA because type 2 inhibitors (typical in AHA) don't show the log-linear relationship the assay assumes 3. This explains why inhibitor titers often fail to predict bleeding severity or treatment response 3.

Confounding Factors to Exclude

Several conditions can mimic or coexist with AHA:

• Lupus anticoagulant - can coexist with AHA and confound diagnosis 4
• Direct oral anticoagulants (DOACs) - can prolong aPTT and confuse the picture 4
• Heparin therapy - must be ruled out 1
• Other factor deficiencies - hence the need for comprehensive factor assays 1

Distinguishing Features from Congenital Hemophilia

• Hemarthrosis is rare in AHA, unlike congenital severe hemophilia A where it's the hallmark 2
• Bleeding pattern differs - more subcutaneous hematomas and muscle bleeds in AHA 2
• Age of onset - typically elderly adults or postpartum women, not childhood 2

When to Suspect AHA

Maintain high clinical suspicion in:

• Elderly patients with new-onset bleeding and prolonged aPTT
• Postpartum women with unexplained bleeding
• Patients with autoimmune diseases, malignancy, or recent infections presenting with bleeding 2
• Any patient with isolated prolonged aPTT before surgery or procedures - even without bleeding 3
• Approximately 50% of cases are idiopathic with no identifiable underlying condition 2

Laboratory Monitoring Requirements

Close collaboration between clinicians and laboratory staff is essential 1. Communication should ensure:

• Appropriate timing of mixing studies (immediate and delayed)
• Proper heat inactivation when indicated
• Consideration of interfering substances
• Selection of appropriate assays if newer therapies are being used 4

The diagnosis requires prompt recognition because mortality exceeds 20% without appropriate treatment 2, making immediate hospitalization and management essential once suspected 5.